Stemgent and Miltenyi Biotec Announce Strategic Partnership

BOSTON, Massachusetts and BERGISCH GLADBACH, Germany, May 4, 2010 - Stemgent, Inc., and Miltenyi Biotec today announced a strategic
collaboration for co-development and commercialization of stem cell research
products.

Within the strategic partnership, Miltenyi Biotec will be responsible for
worldwide marketing and sales of Stemgent's existing stem cell product
portfolio outside the USA, whereas Stemgent will continue to serve its US
customers. Both companies will jointly develop innovative products to serve
unmet needs of the international stem cell research community. New products
developed in the strategic collaboration will be globally commercialized by
Miltenyi Biotec on an exclusive basis.

Miltenyi Biotec will make an equity investment into Stemgent, and Stefan
Miltenyi, CEO of Miltenyi Biotec, will join Stemgent's Board of Directors.
"We are very pleased to form this relationship with Stemgent," said Stefan
Miltenyi. "Stemgent's accomplished track record in identifying superior tools
for stem cell research perfectly complements Miltenyi Biotec's scientific
expertise and commitment to serving the biomedical research community with
innovative high-quality products throughout the world."

Commenting on the collaboration, Ian Ratcliffe, President and CEO of
Stemgent, said, "Partnering with Miltenyi Biotec is a tremendous step for
Stemgent, as we instantly increase our global reach with a top-tier partner
allowing us to better serve our customers' needs. The co-development aspect
dramatically increases our ability to combine Miltenyi Biotec's corporate
technologies with Stemgent's stem cell expertise. We are especially pleased
to have Stefan join Stemgent's board and welcome Miltenyi Biotec as a
strategic partner; Stefan's experience in building a world class organization
in the research tools space brings an invaluable perspective as we continue
to build Stemgent."

About Miltenyi Biotec

Miltenyi Biotec's company mission is to improve scientific understanding
and medical progress by providing products and services for cellular
therapies. With approx. 1100 employees in 18 countries, Miltenyi Biotec
develops, manufactures and commercializes innovations for both, research and
clinical applications. The portfolio provides integrated solutions for all
areas covering sample preparation, cell separation, cell culture, flow
cytometry, and molecular analysis. Visit www.miltenyibiotec.com to
discover more.

About Stemgent

Stemgent advances stem cell science by providing proprietary reagents and
tools developed by some of the world's leading stem cell scientists.
Stemgent's product offering has been specifically optimized for and screened
against stem cells, and includes small molecules for pluripotency,
self-renewal, and differentiation, viral-delivered transcription factors,
matrices, cell lines, cytokines, antibodies, transfection reagents, and more.
This unique product mix is designed to serve researchers who study stem cell
biology and regenerative medicine, and those who use cells derived from stem
cells as tools to advance their understanding of major diseases. With dual
headquarters in Boston, Massachusetts, and San Diego, California, Stemgent is
well positioned to serve these major research markets. For more information
on Stemgent, please visit: www.stemgent.com.

    Contacts:

    Miltenyi Biotec
    Prof. Dr. Uwe Heinlein, Corporate Communications, Miltenyi Biotec GmbH
    +49-2204-8306-6590
    uweh@miltenyibiotec.de 

    Stemgent
    Edward D. Agne, The Communications Strategy Group
    +1-781-631-3117
    edagne@comstratgroup.com

Contacts: Miltenyi Biotec, Prof. Dr. Uwe Heinlein, Corporate Communications, Miltenyi Biotec GmbH, +49-2204-8306-6590, uweh at miltenyibiotec.de . Stemgent, Edward D. Agne, The Communications Strategy Group, +1-781-631-3117, edagne at comstratgroup.com .